Research programme: anticancer monoclonal antibodies - Champions Oncology/Morphotek

Drug Profile

Research programme: anticancer monoclonal antibodies - Champions Oncology/Morphotek

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Morphotek
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 04 Apr 2011 Champions Biotechnology is now called Champions Oncology
  • 03 Nov 2010 Champions Biotechnology receives Qualifying Therapeutics Discovery Project grant from the US Department of Health and Human Services for oncology candidate drug development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top